Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company
focused on improving cardiovascular health, today announced that
Vascepa® (icosapent ethyl) and its landmark cardiovascular outcomes
trial, REDUCE-IT™ (Reduction of Cardiovascular Events With EPA -
Intervention Trial), is scheduled to be featured prominently at the
National Lipid Association (NLA) Scientific Sessions in Miami, May
16-19. NLA’s mission is to enhance the practice of lipid management
in clinical medicine.
One of three late-breaker sessions at this
annual meeting, on Saturday, May 18, 4:40-4:50 p.m. ET, is devoted
to an encore presentation of the unprecedented results of the
REDUCE-IT cardiovascular outcomes study by Christie Ballantyne, MD,
Vice Chair of Research at the Baylor College of Medicine. In
particular, this presentation will include the total events
analysis from the REDUCE-IT study, as first presented March 2019
and published in the Journal of the American College of
Cardiology.1 This analysis showed that Vascepa provided a
statistically significant 30% risk reduction in total (first and
subsequent) cardiovascular events compared to placebo in the
statin-treated patient population studied in REDUCE-IT, resulting
in an average of approximately one fewer major adverse
cardiovascular events per six patients treated with Vascepa
compared to placebo over a five-year period.
“REDUCE-IT results should have a major impact on
clinical practice and I am pleased to be sharing these results with
many of the top physicians in lipid management,” said Dr.
Ballantyne. “Because of the groundbreaking nature of the results,
it is good to also see discussion scheduled at NLA on how best to
use Vascepa with the right patients.”
On Saturday, May 18, 11:00 a.m.-12:45 p.m. ET
there will be a session titled, “REDUCE-IT to Practice ‒ Debate.”
This session highlights that REDUCE-IT showed cardiovascular
benefits from Vascepa which were both significant in magnitude and
seemingly independent of triglyceride levels. As more physicians
become aware of these results, such a session will promote
discussion of how to best use Vascepa in clinical treatment
practice for the preventative care of patients at risk for
cardiovascular disease.
In addition to these significant sessions,
Amarin has sponsored four other poster presentations at the NLA
Scientific Sessions on various cardiovascular disease-related
topics.
About Amarin
Amarin Corporation plc. is a rapidly growing,
innovative pharmaceutical company focused on developing
therapeutics to improve cardiovascular health. Amarin’s product
development program leverages its extensive experience in
polyunsaturated fatty acids and lipid science. Vascepa (icosapent
ethyl) is Amarin's first FDA-approved drug and is available by
prescription in the United States, Lebanon and the United Arab
Emirates. Amarin’s commercial partners are pursuing additional
regulatory approvals for Vascepa in Canada, China and the Middle
East. For more information about Amarin, visit
www.amarincorp.com.
About REDUCE-IT
REDUCE-IT2, an 8,179-patient cardiovascular
outcomes study, was completed in 2018. REDUCE-IT was the first
multinational cardiovascular outcomes study that evaluated the
effect of prescription pure EPA therapy as an add-on to statins in
patients with high cardiovascular risk who, despite stable statin
therapy, had elevated triglyceride levels (at least 135 mg/dL). A
large portion of the male and female patients enrolled in this
outcomes study were diagnosed with type 2 diabetes.
More information on the REDUCE-IT study results
can be found at www.amarincorp.com.
About Cardiovascular
Disease
Worldwide, cardiovascular disease (CVD) remains
the #1 killer of men and women. In the United States CVD leads to
one in every three deaths – one death approximately every 38
seconds – with annual treatment cost in excess of $500 billion.3,
4
Multiple primary and secondary
prevention trials have shown a significant reduction of 25% to
35% in the risk of cardiovascular
events with statin therapy, leaving significant
persistent residual risk despite the achievement of target LDL-C
levels.5
Beyond the cardiovascular risk associated with
LDL-C, genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood),
and TG-rich lipoproteins, are at increased risk for cardiovascular
disease. 6-9
About Vascepa® (icosapent ethyl)
Capsules
Vascepa (icosapent ethyl) capsules are a
single-molecule prescription product consisting of the omega-3 acid
commonly known as EPA in ethyl-ester form. Vascepa is not fish oil,
but is derived from fish through a stringent and complex
FDA-regulated manufacturing process designed to effectively
eliminate impurities and isolate and protect the single molecule
active ingredient from degradation. Vascepa, known in scientific
literature as AMR101, has been designated a new chemical entity by
the FDA. Amarin has been issued multiple patents internationally
based on the unique clinical profile of Vascepa, including the
drug’s ability to lower triglyceride levels in relevant patient
populations without raising LDL-cholesterol levels.
Indication and Usage Based on Current
FDA-Approved Label (not including REDUCE-IT results)
- Vascepa (icosapent ethyl) is
indicated as an adjunct to diet to reduce triglyceride (TG) levels
in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.
- The effect of Vascepa on the risk
for pancreatitis and cardiovascular mortality and morbidity in
patients with severe hypertriglyceridemia has not been
determined.
Important Safety Information for Vascepa Based
on Current FDA-Approved Label (not including REDUCE-IT results)
(Includes Data from Two 12-Week Studies (n=622) (MARINE and ANCHOR)
of Patients with Triglycerides Values of 200 to 2000 mg/dL)
- Vascepa is contraindicated in
patients with known hypersensitivity (e.g., anaphylactic reaction)
to Vascepa or any of its components.
- In patients with hepatic
impairment, monitor ALT and AST levels periodically during
therapy.
- Use with caution in patients with
known hypersensitivity to fish and/or shellfish.
- The most common reported adverse
reaction (incidence >2% and greater than placebo) was arthralgia
(2.3% for Vascepa, 1.0% for placebo). There was no reported adverse
reaction >3% and greater than placebo.
- Adverse events and product
complaints may be reported by calling 1-855-VASCEPA or the FDA at
1-800-FDA-1088.
- Patients receiving treatment with
Vascepa and other drugs affecting coagulation (e.g., anti-platelet
agents) should be monitored periodically.
- Patients should be advised to
swallow Vascepa capsules whole; not to break open, crush, dissolve,
or chew Vascepa.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE
FOUND AT WWW.VASCEPA.COM.
Important Safety Information for Vascepa based on REDUCE-IT, as
previously reported in The New England Journal of Medicine2
publication of the primary results of the REDUCE-IT study:
- Excluding the major adverse cardiovascular events (MACE)
results described above, overall adverse event rates in REDUCE-IT
were similar across the statin plus Vascepa and the statin plus
placebo treatment groups.
- There were no significant differences between treatments in the
overall rate of treatment emergent adverse events or serious
adverse events leading to withdrawal of study drug.
- There was no serious adverse event (SAE) occurring at a
frequency of >2% which occurred at a numerically higher rate in
the statin plus Vascepa treatment group than in the statin plus
placebo treatment group.
- Adverse events (AEs) occurring in 5% or greater of patients and
more frequently with Vascepa than placebo were:– peripheral
edema (6.5% Vascepa patients versus 5.0% placebo patients),
although there was no increase in the rate of heart failure in
Vascepa patients– constipation (5.4% Vascepa patients
versus 3.6% placebo patients), although mineral oil, as used as
placebo, is known to lower constipation, and– atrial
fibrillation (5.3% Vascepa patients versus 3.9% placebo patients),
although there were reductions in rates of cardiac arrest, sudden
death and myocardial infarctions observed in Vascepa patients
- There were numerically more SAEs related to bleeding in the
statin plus Vascepa treatment group although overall rates were low
with no fatal bleeding observed in either group and no significant
difference in adjudicated hemorrhagic stroke or serious central
nervous system or gastrointestinal bleeding events between
treatments.
- In summary, Vascepa was well tolerated with a safety profile
generally consistent with clinical experience associated with
omega-3 fatty acids and current FDA-approved labeling of such
products.
Vascepa has been approved for use by the United
States Food and Drug Administration (FDA) as an adjunct to diet to
reduce triglyceride levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia. FDA has not reviewed and opined on a
supplemental new drug application related to REDUCE-IT. FDA has not
reviewed the information herein or determined whether to approve
Vascepa for use to reduce the risk of MACE. Nothing in this press
release should be construed as promoting the use of Vascepa in any
indication that has not been approved by the FDA.
Important Cautionary Information About
These Data
Further REDUCE-IT data assessment and data
release could yield additional useful information to inform greater
understanding of the trial outcome. Further detailed data
assessment by Amarin and regulatory authorities will
continue and take several months to complete and record. The final
evaluation of the totality of the efficacy and safety data from
REDUCE-IT may include some or all of the following, as well as
other considerations: new information affecting the degree of
treatment benefit on studied endpoints; study conduct and data
robustness, quality, integrity and consistency; additional safety
data considerations and risk/benefit considerations; consideration
of REDUCE-IT results in the context of other clinical studies.
Recurrent event analyses for the total primary
endpoint events and for the total key secondary endpoint in
REDUCE-IT as published in the Journal of the American College of
Cardiology1 were conducted using a series of statistical models.
These analyses were tertiary or exploratory endpoints; most of the
models used were prespecified and one was post hoc. Each recurrent
event statistical model has inherent strengths and weaknesses, with
no single model considered definitive or outperforming the other
models, and this is an evolving field of science. Nonetheless,
results from the total primary and total key secondary endpoint
events analyses are consistent across the various recurrent event
statistical models and are also consistent with the original
primary and secondary endpoint results. Together, the REDUCE-IT
recurrent event analyses and the original primary and key secondary
endpoint analyses support the robustness of the clinical benefit of
Vascepa therapy in reducing cardiovascular risk.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements related to the potential impact of
Vascepa on patient care, cardiovascular risk in particular patient
groups and data suggesting the potential benefits of Vascepa. These
forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that
could cause actual results to differ materially from those
described or projected herein include the following: uncertainties
associated generally with data of this type, research and
development, clinical trials and related regulatory approvals; the
risk that sales of Vascepa may not meet expectations and the risk
that patents may not be upheld in patent litigation and
applications may not result in issued patents sufficient to protect
the Vascepa franchise. A further list and description of
these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin's filings with the U.S.
Securities and Exchange Commission, including its most recent
quarterly report on Form 10-Q. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
|
References |
1 |
Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on
Total Ischemic Events: From REDUCE-IT. J Am Coll
Cardiol 2019. epub ahead of print. |
|
https://doi.org/10.1016/j.jacc.2019.02.032. |
2 |
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction
with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med
2019;380:11-22. |
3 |
American Heart Association. 2018. Disease and Stroke
Statistics-2018 Update. |
4 |
American Heart Association. 2017. Cardiovascular disease: A costly
burden for America projections through 2035. |
5 |
Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive
dyslipidemia therapy in hypertriglyceridemia management. J Am Coll
Cardiol. 2018;72(3):330-343. |
6 |
Budoff M. Triglycerides and triglyceride-rich lipoproteins in the
causal pathway of cardiovascular disease. Am J Cardiol.
2016;118:138-145. |
7 |
Toth PP, Granowitz C, Hull M, et al. High triglycerides are
associated with increased cardiovascular events, medical costs, and
resource use: A real-world administrative claims analysis of
statin-treated patients with high residual cardiovascular risk. J
Am Heart Assoc. 2018;7(15):e008740. |
8 |
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic
cardiovascular disease - New insights from epidemiology, genetics,
and biology. Circ Res. 2016;118:547-563. |
9 |
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease.
Lancet. 2014;384:626–635. |
|
|
Amarin Contact Information
Investor Relations:Elisabeth SchwartzInvestor Relations and
Corporate CommunicationsAmarin Corporation plcIn U.S.: +1
(908) 719-1315investor.relations@amarincorp.com (investor
inquiries)PR@amarincorp.com (media inquiries)
Lee M. Stern Solebury Trout In U.S.: +1 (646)
378-2992lstern@soleburytrout.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024